We are pleased to announce that famed American Geneticist George Church will be joining Alveo’s Scientific Advisory Board. With extensive background in medical diagnostics, including founding application-based companies, George will bring valuable expertise to our Board as we continue to grow and democratize our healthcare system.
“At Alveo, we are focused on intercepting the spread of infectious diseases utilizing agile and dynamic technology that brings rapid diagnosis to Everyone, Anytime, Everywhere™,” said Ron Chiarello, PhD, Fouder and CEO of Alveo. “To support this, we continue to add scientific leaders that have deep diagnostic and healthcare background and complement our consumer-driven approach to rapidly connect consumers, health professionals and treatment providers in real-time with fast and accurate results. George has an incredible understanding of our industry and we are fortunate to have his perspectives as we continue to scale Alveo.”
“Alveo has an unparalleled focus on diagnosis and surveillance for Flu A/B, COVID-19, and RSV,” said George Church, Scientific Advisory Board Member, Alveo. “I am honored to serve on the Board and look forward to contributing to the company’s work as it continues to expand the diagnostic services it offers.”
George Church brings deep knowledge of related research and strategic and operational business prowess to Alveo. He is known for his professional contributions in the sequencing of genomes and interpreting such data, in synthetic biology and genome engineering.
Mr. Church is currently the Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world’s only open-access information on human Genomic, Environmental & Trait data (GET).
His 1984 Harvard, PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in 1994. His innovations have contributed to nearly all “next generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore).
This plus his lab’s work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics (Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics) & synthetic biology / therapeutics (Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive). He has also pioneered new privacy, biosafety, ELSI, environmental & biosecurity policies.
Mr. Church is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 537 papers, 156 patent publications & one book (Regenesis).
George’s addition to the Scientific Advisory Board reflects our continued vision to bring together the best diagnostic and healthcare leaders to help democratize our healthcare system.
Over the past several months, an impressive group of seasoned leaders has joined our Board.
By Ron Chiarello, PhD, Founder and CEO of Alveo